Vertex Pharmaceuticals Stock: Is Wall Street Bullish or Bearish?

Core Insights - Vertex Pharmaceuticals is a global biotechnology firm focused on developing transformative medicines for serious diseases, particularly cystic fibrosis and genetic disorders, with a market cap of approximately $124.8 billion [1] Stock Performance - Over the past 52 weeks, Vertex shares have gained 6.3%, underperforming the S&P 500 Index which increased by 11.8%. However, year-to-date, the stock has risen 8.4%, outperforming the S&P 500's slight decline [2] - The Health Care Select Sector SPDR Fund has gained 7.7% over the past 52 weeks and 1.9% year-to-date, indicating a mixed performance relative to the sector [3] Financial Performance - In Q4 2025, Vertex reported a revenue growth of 10%, driven by its cystic fibrosis franchise and new products, which has positively influenced investor sentiment [5] - For the fiscal year ending December 2026, analysts project Vertex's EPS to grow by 6.2% year-over-year to $17.49, with a mixed earnings surprise history [6] Analyst Ratings and Price Targets - Among 32 analysts covering Vertex, the consensus rating is a "Moderate Buy," consisting of 22 "Strong Buy" ratings, two "Moderate Buys," seven "Holds," and one "Strong Sell" [6] - Recently, Cantor Fitzgerald raised its price target for Vertex from $485 to $590, maintaining an "Overweight" rating due to confidence in the company's renal franchise expansion [7]